Payment overview · 2025
General Payments
5 reported records · 2 companies
Healthcare provider profile · identity verified
Allopathic & Osteopathic Physicians|Internal Medicine · HARTFORD, CT · NPI 1689786568
Verified facts
CMS Open Payments records show John S Wisniewski, MD received $89.31 in general payments during 2025 across 5 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 65.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 253 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Payment overview · 2025
5 reported records · 2 companies
Separate record types
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $58.01 | 65.0% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $31.30 | 35.0% | 2 | 2025 |
What were the payments for?
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $89.31 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $58.01 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.96 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 253 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
253 | 46 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1159 | 316 |
| Amlodipine Besylate | Amlodipine Besylate | 701 | 192 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 568 | 150 |
| Levothyroxine Sodium | Levothyroxine Sodium | 481 | 126 |
| Losartan Potassium | Losartan Potassium | 347 | 99 |
| Hydrochlorothiazide | Hydrochlorothiazide | 301 | 87 |
| Metformin Hcl | Metformin Hcl | 292 | 78 |
| Allopurinol | Allopurinol | 279 | 74 |
| Ozempic | Semaglutide | 253 | 46 |
| Lisinopril | Lisinopril | 242 | 70 |
| Metoprolol Succinate | Metoprolol Succinate | 240 | 70 |
| Omeprazole | Omeprazole | 234 | 65 |
| Simvastatin | Simvastatin | 231 | 61 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 215 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 207 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 177 | 50 |
| Valsartan | Valsartan | 168 | 41 |
| Synthroid | Levothyroxine Sodium | 156 | 40 |
| Gabapentin | Gabapentin | 154 | 42 |
| Metformin Hcl Er | Metformin Hcl | 153 | 43 |
| Furosemide | Furosemide | 143 | 45 |
| Mounjaro | Tirzepatide | 143 | 22 |
| Tramadol Hcl | Tramadol Hcl | 141 | 32 |
| Ezetimibe | Ezetimibe | 127 | 37 |
| Atenolol | Atenolol | 126 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 120 | 34 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 115 | 35 |
| Trazodone Hcl | Trazodone Hcl | 114 | 37 |
| Eliquis | Apixaban | 113 | 28 |
| Oxycodone Hcl | Oxycodone Hcl | 110 | 14 |
| Carvedilol | Carvedilol | 108 | 31 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 103 | 26 |
| Nebivolol Hcl | Nebivolol Hcl | 99 | 25 |
| Spironolactone | Spironolactone | 97 | 28 |
| Alprazolam | Alprazolam | 93 | 31 |
| Sertraline Hcl | Sertraline Hcl | 92 | 21 |
| Prednisone | Prednisone | 90 | 43 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 87 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 87 | 13 |
| Lorazepam | Lorazepam | 86 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 86 | 24 |
| Clonazepam | Clonazepam | 84 | 13 |
| Chlorthalidone | Chlorthalidone | 83 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 82 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 81 | 21 |
| Trulicity | Dulaglutide | 80 | 13 |
| Bupropion Xl | Bupropion Hcl | 74 | 20 |
| Farxiga | Dapagliflozin Propanediol | 74 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 73 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 72 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 71 | 19 |
| Finasteride | Finasteride | 70 | 17 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 69 | 18 |
| Mirtazapine | Mirtazapine | 68 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 65 | 14 |
| Montelukast Sodium | Montelukast Sodium | 63 | 18 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 61 | 14 |
| Pregabalin | Pregabalin | 56 | 14 |
| Diazepam | Diazepam | 55 | 13 |
| Irbesartan | Irbesartan | 55 | 16 |
| Xarelto | Rivaroxaban | 55 | 11 |
| Januvia | Sitagliptin Phosphate | 54 | suppressed |
| Glimepiride | Glimepiride | 53 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 52 | 15 |
| Famotidine | Famotidine | 51 | suppressed |
| Nystatin | Nystatin | 51 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | 12 |
| Jardiance | Empagliflozin | 48 | 14 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 44 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 44 | suppressed |
| Potassium Chloride | Potassium Chloride | 44 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 44 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 21 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 43 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 41 | 11 |
| Alendronate Sodium | Alendronate Sodium | 40 | 13 |
| Lidocaine | Lidocaine | 40 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 38 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 38 | 33 |
| Hydralazine Hcl | Hydralazine Hcl | 38 | suppressed |
| Lansoprazole | Lansoprazole | 36 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 35 | suppressed |
| Torsemide | Torsemide | 35 | 12 |
| Methocarbamol | Methocarbamol | 33 | 11 |
| Valacyclovir | Valacyclovir Hcl | 33 | 20 |
| Baclofen | Baclofen | 32 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 31 | suppressed |
| Cephalexin | Cephalexin | 30 | 25 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Meloxicam | Meloxicam | 28 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 28 | 13 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 27 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 26 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 25 | suppressed |
| Eszopiclone | Eszopiclone | 25 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 25 | suppressed |
| Ramipril | Ramipril | 25 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Olanzapine | Olanzapine | 23 | suppressed |
| Temazepam | Temazepam | 23 | suppressed |
| Gemtesa | Vibegron | 22 | suppressed |
| Nateglinide | Nateglinide | 22 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 17 |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Telmisartan | Telmisartan | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 18 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Azathioprine | Azathioprine | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | 11 |
| Desloratadine | Desloratadine | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Invokana | Canagliflozin | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Ursodiol | Ursodiol | 13 | suppressed |
| Azithromycin | Azithromycin | 12 | 12 |
| Cefadroxil | Cefadroxil | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | 11 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Sf | Fluoride (Sodium) | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Serevent Diskus | Salmeterol Xinafoate | 11 | suppressed |
Timeline
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $89.31 · 5 records | Bayer Healthcare Pharmaceuticals Inc. | Kerendia, Ozempic, Rybelsus | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error